Table 4.
p53 status in K243R/+ tumors
| Tumor | Sex | Age | Mutationa | Mutanta | Effect | p_domainb |
| wk | ||||||
| Hepatocellular carcinoma 1 | Male | 61 | c.163ins_T | STOP 55 | Insertion | TAD |
| Hepatocellular carcinoma 2 | Male | 117 | c.242C>Tc.301C>T | p.A81Vp.Q101X | MissenseNonsense | PRDDBD |
| Sarcoma 1 | Male | 69 | c.163ins_Tc.296ins_A | STOP 55STOP 99 | InsertionInsertion | TADDBD |
| Sarcoma 2 | Female | 122 | c.296ins_Ac.467C>T | STOP 99p.A156V | InsertionMissense | DBDDBD |
| B cell lymphoma 1 | Female | 62 | c.359-365del7 | STOP 128 | Deletion | DBD |
| B cell lymphoma 2 | Female | 119 | c.109T>C;980T>Cc.429G>A | p.S37P;L327Pp.W143X | MissenseNonsense | TAD, 4DDBD |
| B cell lymphoma 3 | Female | 139 | c.443C>T | p.P148L | Missense | DBD |
| Leukemia 1 | Female | 57 | c.1064A>Gc.841A>G | p.E355Gp.T281A | MissenseMissense | DBDDBD |
a
Mutation nomenclatures follow the Human Genome Variation Society recommendations. c, coding sequence; ins, insertion; del, deletion; p, protein sequence. p53 status was determined by the nucleotide sequencing of four to five clones derived from each tumor.
b
Protein domain with mutation indicated. TAD, transactivation domain; PRD, proline-rich domain; DBD, DNA-binding domain; 4D, tetramerization domain.